Latest Thesis
Xenon Pharmaceuticals: epilepsy pipeline optionality with the cash clock in view
Xenon filed a 2025 operating loss of $373.1 million, a 2025 net loss of $345.9 million and Q1 2026 cash of $545.9 million. The thesis depends on clinical execution, regulatory progress and how long the balance sheet can fund development.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.